These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
497 related articles for article (PubMed ID: 23258843)
1. The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells. Johannessen TC; Prestegarden L; Grudic A; Hegi ME; Tysnes BB; Bjerkvig R Neuro Oncol; 2013 Mar; 15(3):269-78. PubMed ID: 23258843 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma. Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370 [TBL] [Abstract][Full Text] [Related]
3. TP53 regulates human AlkB homologue 2 expression in glioma resistance to Photofrin-mediated photodynamic therapy. Lee SY; Luk SK; Chuang CP; Yip SP; To SS; Yung YM Br J Cancer; 2010 Jul; 103(3):362-9. PubMed ID: 20661249 [TBL] [Abstract][Full Text] [Related]
4. JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression. Okada M; Sato A; Shibuya K; Watanabe E; Seino S; Suzuki S; Seino M; Narita Y; Shibui S; Kayama T; Kitanaka C Int J Oncol; 2014 Feb; 44(2):591-9. PubMed ID: 24316756 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways. Sun S; Lee D; Ho AS; Pu JK; Zhang XQ; Lee NP; Day PJ; Lui WM; Fung CF; Leung GK Neuro Oncol; 2013 May; 15(5):562-77. PubMed ID: 23444257 [TBL] [Abstract][Full Text] [Related]
6. STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression. Kohsaka S; Wang L; Yachi K; Mahabir R; Narita T; Itoh T; Tanino M; Kimura T; Nishihara H; Tanaka S Mol Cancer Ther; 2012 Jun; 11(6):1289-99. PubMed ID: 22532597 [TBL] [Abstract][Full Text] [Related]
7. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma. Tian T; Mingyi M; Qiu X; Qiu Y Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996 [TBL] [Abstract][Full Text] [Related]
8. A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells. Ahmed EM; Bandopadhyay G; Coyle B; Grabowska A Cell Oncol (Dordr); 2018 Jun; 41(3):319-328. PubMed ID: 29492900 [TBL] [Abstract][Full Text] [Related]
9. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. Agnihotri S; Gajadhar AS; Ternamian C; Gorlia T; Diefes KL; Mischel PS; Kelly J; McGown G; Thorncroft M; Carlson BL; Sarkaria JN; Margison GP; Aldape K; Hawkins C; Hegi M; Guha A J Clin Invest; 2012 Jan; 122(1):253-66. PubMed ID: 22156195 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase. Gao Y; Fotovati A; Lee C; Wang M; Cote G; Guns E; Toyota B; Faury D; Jabado N; Dunn SE Mol Cancer Ther; 2009 Dec; 8(12):3276-84. PubMed ID: 19996271 [TBL] [Abstract][Full Text] [Related]
11. Hyperoxia resensitizes chemoresistant glioblastoma cells to temozolomide through unfolded protein response. Lee D; Sun S; Ho AS; Kiang KM; Zhang XQ; Xu FF; Leung GK Anticancer Res; 2014 Jun; 34(6):2957-66. PubMed ID: 24922660 [TBL] [Abstract][Full Text] [Related]
12. Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide. Chai KM; Wang CY; Liaw HJ; Fang KM; Yang CS; Tzeng SF Oncotarget; 2014 Nov; 5(21):10901-15. PubMed ID: 25337721 [TBL] [Abstract][Full Text] [Related]
13. Aldehyde dehydrogenase 1A1--a new mediator of resistance to temozolomide in glioblastoma. Schäfer A; Teufel J; Ringel F; Bettstetter M; Hoepner I; Rasper M; Gempt J; Koeritzer J; Schmidt-Graf F; Meyer B; Beier CP; Schlegel J Neuro Oncol; 2012 Dec; 14(12):1452-64. PubMed ID: 23132408 [TBL] [Abstract][Full Text] [Related]
14. Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors. Wang Z; Yang J; Xu G; Wang W; Liu C; Yang H; Yu Z; Lei Q; Xiao L; Xiong J; Zeng L; Xiang J; Ma J; Li G; Wu M Oncotarget; 2015 Feb; 6(5):3147-64. PubMed ID: 25605243 [TBL] [Abstract][Full Text] [Related]
15. Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma. Gil Del Alcazar CR; Todorova PK; Habib AA; Mukherjee B; Burma S Mol Cancer Res; 2016 Oct; 14(10):928-940. PubMed ID: 27358111 [TBL] [Abstract][Full Text] [Related]
16. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952 [TBL] [Abstract][Full Text] [Related]
17. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma. Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts. Kitange GJ; Mladek AC; Carlson BL; Schroeder MA; Pokorny JL; Cen L; Decker PA; Wu W; Lomberk GA; Gupta SK; Urrutia RA; Sarkaria JN Clin Cancer Res; 2012 Aug; 18(15):4070-9. PubMed ID: 22675172 [TBL] [Abstract][Full Text] [Related]
19. Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide. Li H; Yuan X; Yan D; Li D; Guan F; Dong Y; Wang H; Liu X; Yang B Cell Physiol Biochem; 2017; 42(3):1192-1201. PubMed ID: 28668966 [TBL] [Abstract][Full Text] [Related]
20. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]